Neuron23 raises $100m to advance Parkinson’s disease therapy
The company intends to commence the trials of NEU-723 to potentially treat Parkinson's disease by the end of this year.
Central Nervous System
Latest in
Central Nervous System
Biogen and Eisai revise agreements on Alzheimer’s disease therapies
The lecanemab collaboration was revised with the product supply agreement being extended from five to ten years.
AbbVie and Richter partner to develop neuropsychiatric diseases therapies
The partnership includes preclinical and clinical R&D works with financing to be shared by the companies.
Novartis and Voyager sign licence agreement for gene therapy capsids
Voyager will be eligible to earn up to $1.5bn on meeting potential development, regulatory and commercial milestones from Novartis.
Vydura gains positive CHMP nod for migraine, but faces tough competition ahead
Vydura will become the first CGRP receptor antagonist available in Europe if approved by the European Medicines Agency (EMA).
By
How horizon scanning can help predict the future for EU’s Alzheimer’s disease market
Aduhelm’s US launch has prompted a new look into what is in store for the Alzheimer’s disease market over the…
By
Sarepta and GenEdit partner to develop neuromuscular disease therapies
Though the deal, Sarepta will gain exclusive option rights for licensing polymer nanoparticles developed by GenEdit.
New multiple sclerosis discovery benefits already successful Moderna
Moderna’s developing mRNA-1189 vaccine could help prevent multiple sclerosis, though it is not yet approved for the indication.
By